Literature DB >> 20118772

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

David S Klimstra1, Irvin R Modlin, N Volkan Adsay, Runjan Chetty, Vikram Deshpande, Mithat Gönen, Robert T Jensen, Mark Kidd, Matthew H Kulke, Ricardo V Lloyd, Cesar Moran, Steven F Moss, Kjell Oberg, Dermot O'Toole, Guido Rindi, Marie E Robert, Saul Suster, Laura H Tang, Chin-Yuan Tzen, Mary Kay Washington, Betram Wiedenmann, James Yao.   

Abstract

Epithelial neuroendocrine tumors (NETs) have been the subject of much debate regarding their optimal classification. Although multiple systems of nomenclature, grading, and staging have been proposed, none has achieved universal acceptance. To help define the underlying common features of these classification systems and to identify the minimal pathology data that should be reported to ensure consistent clinical management and reproducibility of data from therapeutic trials, a multidisciplinary team of physicians interested in NETs was assembled. At a group meeting, the participants discussed a series of "yes" or "no" questions related to the pathology of NETs and the minimal data to be included in the reports. After discussion, anonymous votes were taken, using the Delphic principle that 80% agreement on a vote of either yes or no would define a consensus. Questions that failed to achieve a consensus were rephrased once or twice and discussed, and additional votes were taken. Of 108 questions, 91 were answerable either yes or no by more than 80% of the participants. There was agreement about the importance of proliferation rate for tumor grading, the landmarks to use for staging, the prognostic factors assessable by routine histology that should be reported, the potential for tumors to progress biologically with metastasis, and the current status of advanced immunohistochemical and molecular testing for treatment-related biomarkers. The lack of utility of a variety of immunohistochemical stains and pathologic findings was also agreed upon. A consensus could not be reached for the remaining 17 questions, which included both minor points related to extent of disease assessment and some major areas such as terminology, routine immunohistochemical staining for general neuroendocrine markers, use of Ki67 staining to assess proliferation, and the relationship of tumor grade to degree of differentiation. On the basis of the results of the Delphic voting, a minimum pathology data set was developed. Although there remains disagreement among experts about the specific classification system that should be used, there is agreement about the fundamental pathology data that should be reported. Examination of the areas of disagreement reveals significant opportunities for collaborative study to resolve unanswered questions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118772     DOI: 10.1097/PAS.0b013e3181ce1447

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  102 in total

Review 1.  Clinical pathways for pancreatic neuroendocrine tumors.

Authors:  Angela Alistar; Max Sung; Michelle Kim; Randall F Holcombe
Journal:  J Gastrointest Cancer       Date:  2012-12

2.  [The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment].

Authors:  G Klöppel; G Rindi; A Perren; P Komminoth; D S Klimstra
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

3.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

4.  The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement.

Authors:  Günter Klöppel; Guido Rindi; Aurel Perren; Paul Komminoth; David S Klimstra
Journal:  Virchows Arch       Date:  2010-04-27       Impact factor: 4.064

Review 5.  Management of functional neuroendocrine tumors of the pancreas.

Authors:  Kjell Öberg
Journal:  Gland Surg       Date:  2018-02

6.  Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.

Authors:  Annika Blank; Laura Wehweck; Ilaria Marinoni; Laura Amanda Boos; Frank Bergmann; Anja Maria Schmitt; Aurel Perren
Journal:  Virchows Arch       Date:  2015-09-17       Impact factor: 4.064

Review 7.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

Review 8.  Cutaneous metastases as an initial manifestation of visceral well-differentiated neuroendocrine tumor: a report of four cases and a review of literature.

Authors:  Jaroslaw Jedrych; Klaus Busam; David S Klimstra; Melissa Pulitzer
Journal:  J Cutan Pathol       Date:  2013-12-03       Impact factor: 1.587

9.  Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.

Authors:  Ashlie Nadler; Moises Cukier; Corwyn Rowsell; Sepideh Kamali; Yael Feinberg; Simron Singh; Calvin H L Law
Journal:  Virchows Arch       Date:  2013-04-16       Impact factor: 4.064

10.  Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.

Authors:  Gabriele Carlinfante; Paola Baccarini; Debora Berretti; Tiziana Cassetti; Maurizio Cavina; Rita Conigliaro; Alessandro De Pellegrin; Luca Di Tommaso; Carlo Fabbri; Adele Fornelli; Andrea Frasoldati; Giorgio Gardini; Luisa Losi; Livia Maccio; Raffaele Manta; Nico Pagano; Romano Sassatelli; Silvia Serra; Lorenzo Camellini
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.